Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001764013-26-000092
Filing Date
2026-07-22
Accepted
2026-07-22 16:10:12
Documents
20
Period of Report
2026-09-02

Document Format Files

Seq Description Document Type Size
1 DEF 14A imvt-20260721.htm   iXBRL DEF 14A 1088856
6 imvt-20260721_g1.jpg GRAPHIC 56364
7 imvt-20260721_g2.jpg GRAPHIC 59663
8 imvt-20260721_g3.jpg GRAPHIC 53442
9 imvt-20260721_g4.jpg GRAPHIC 496560
10 imvt-20260721_g5.jpg GRAPHIC 241279
  Complete submission text file 0001764013-26-000092.txt   3978816

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT imvt-20260721.xsd EX-101.SCH 3121
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT imvt-20260721_def.xml EX-101.DEF 4776
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT imvt-20260721_lab.xml EX-101.LAB 4900
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT imvt-20260721_pre.xml EX-101.PRE 4368
23 EXTRACTED XBRL INSTANCE DOCUMENT imvt-20260721_htm.xml XML 147604
Mailing Address 1000 PARK FORTY PLAZA DURHAM NC 27713
Business Address 1000 PARK FORTY PLAZA DURHAM NC 27713 917-410-3120
Immunovant, Inc. (Filer) CIK: 0001764013 (see all company filings)

EIN.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
Type: DEF 14A | Act: 34 | File No.: 001-38906 | Film No.: 261193804
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)